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AbsTrACT
Objective In England, the National Health Service 
commissioned a National Management Service for 
children with primary ciliary dyskinesia (PCD). The aims of 
this study were to describe the health of children seen in 
this Service and compare lung function to children with 
cystic fibrosis (CF).
Design Multi- centre service evaluation of the English 
National Management PCD Service.
setting Four nationally commissioned PCD centres in 
England.
Patients 333 children with PCD reviewed in the Service 
in 2015; lung function data were also compared with 
2970 children with CF.
results Median age at diagnosis for PCD was 2.6 years, 
significantly lower in children with situs inversus (1.0 vs 
6.0 years, p<0.001). Compared with national data from 
the CF Registry, mean (SD) %predicted forced expiratory 
volume in one second (FEV1) was 76.8% in PCD (n=240) 
and 85.0% in CF, and FEV1 was lower in children with 
PCD up to the age of 15 years. Approximately half 
of children had some hearing impairment, with 26% 
requiring hearing aids. Children with a lower body mass 
index (BMI) had lower FEV1 (p<0.001). One- third of 
children had positive respiratory cultures at review, 54% 
of these grew Haemophilus influenzae.
Conclusions We provide evidence that children with 
PCD in England have worse lung function than those 
with CF. Nutritional status should be considered in 
PCD management, as those with a lower BMI have 
significantly lower FEV1. Hearing impairment is common 
but seems to improve with age. Well- designed and 
powered randomised controlled trials on management of 
PCD are needed to inform best clinical practice.
InTrODuCTIOn
Primary ciliary dyskinesia (PCD) is a rare autosomal 
recessive condition where abnormal ciliary function 
leads to impaired mucociliary clearance. This loss 
of function to the mucociliary escalator leads to 
recurrent sinopulmonary infection and, ultimately, 
bronchiectasis. Historically, it has been considered 
a mild respiratory condition; however, recent data 
suggest that lung function declines at a similar rate 
through childhood to children with cystic fibrosis 
(CF).1–3 In addition, about 80% of patients suffer 
with persistent otitis media with effusion and 
associated conductive hearing loss.4 5 Half of the 
patients have situs inversus totalis6 and up to 17% 
have congenital heart disease (CHD).7 8 Many men 
are infertile due to immotile sperm and women can 
have reduced fertility.9 10 The estimated prevalence 
is 1 in 10 000 live births1 11 but this can be signifi-
cantly higher in certain populations.12 13
In 2012, National Health Service England 
commissioned a National Children’s PCD Manage-
ment Service to complement the existing diagnostic 
service.14 Four PCD centres were commissioned 
to undertake annual review assessments, to a stan-
dardised service specification, by a specialist PCD 
multi- disciplinary team (MDT) on all children with 
PCD in England.
Here, we describe the first full set of data 
collected from children at annual review, in 2015. 
We compare the lung function of children with 
PCD to those with CF in England and identify areas 
of future research that will help to improve patient 
care.
What is already known on this topic?
 ► Primary ciliary dyskinesia (PCD) is a rare 
autosomal recessive condition where abnormal 
ciliary function leads to impaired mucociliary 
clearance.
 ► Historically PCD has been considered a mild 
respiratory condition.
 ► There is little evidence to guide the 
management of children with PCD, with only 
one randomised controlled trial published to 
date.
What this study adds?
 ► In England, forced expiratory volume in one 
second (FEV1) was lower in children with 
PCD compared to those with cystic fibrosis, 
particularly in younger age groups.
 ► Nutritional status should be considered in PCD 
management, as those with a lower body mass 
index have significantly lower FEV1.
 ► Hearing impairment is common but seems to 
improve with age.
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Table 1 Clinical and demographic data on children with PCD who 
underwent an annual review in 2015 across the four English National 
Children PCD Management Services
Mean (sD) n with available data
Median age in years (IQr) 9.8 (5.5 to 13.8) 333
Male (%) 175 (52.6%) 333
FEV1 z- score −1.9 (1.4) 240
FEV1 % predicted 76.8% 240
FVC z- score −1.3 (1.5) 240
FVC % predicted 85.4% 240
BMI z- score 0 (1.4) 307
Weight z- score −0.1 (1.3) 159*
Height z- score −0.3 (1.1) 310
Age at diagnosis 2.6 (0.5 to 7.2)† 321
*WHO Weight- for- age reference data are not available beyond age 10 hence n 
lower than for other anthropometric data.27
†Median (IQR).
BMI, body mass index; FEV1, forced expiratory volume in one second; FVC, forced 
vital capacity; PCD, primary ciliary dyskinesia.
MeThODs
Participants
All children with a diagnosis of PCD who had an annual review 
assessment between 1 January and 31 December 2015, in one of 
the four nationally commissioned PCD centres in England were 
included in this study. The diagnosis of PCD was confirmed by 
a specialist PCD diagnostic MDT, in line with European Respi-
ratory Society (ERS) consensus guidelines.14 15 Annual reviews 
were carried out to a standardised service specification.14 16 To 
ensure that children received similar care across centres, national 
guidelines were developed, teams met regularly to discuss clin-
ical cases and clinical outcome data were audited. The project 
was reviewed by the Research and Development office at Univer-
sity Hospital Southampton and was deemed to be a service 
evaluation hence research ethics committee approval was not 
required.17
Data collection
Data were extracted from electronic and paper medical records 
and from annual review reports, using a standardised data sheet, 
agreed a priori, with variables pre- defined in a coding manual. 
These included demographics, diagnostic information and 
a clinical review of the year, focused on respiratory, ear, nose 
and throat (ENT), and cardiac issues. Also collected were data 
on treatments, including airway clearance physiotherapy tech-
niques and adjuncts, nebulised mucolytics, antibiotic use (oral 
and intravenous) both prophylactically and for exacerbations, 
inhalers and nasal treatments; and anthropometry and investi-
gations, including spirometry, audiometry and collection of an 
airway microbiology sample. Centres were contacted to clarify 
any discordant or missing data.
Investigations conducted at annual review assessment
Spirometry data
Equipment was calibrated as per manufacturers’ instructions and 
all measurements were obtained according to the ERS/Amer-
ican Thoracic Society guidelines.18 Global Lung Initiative (GLI) 
equations were used to estimate z- scores for forced expiratory 
volume in one second (FEV1) and forced vital capacity (FVC) 
from the data, ethnicity- specific equations were used where 
available.19 GLI- based FEV1 z- scores were obtained from the UK 
CF Registry for all English children in 2015 for direct compari-
sons with our PCD FEV1 data.
20
Audiology data
Hearing was defined as normal if <20 dB, mild loss if 20–40 dB, 
moderate loss if 40–70 dB, severe loss if 70–95 dB and profound 
loss if >95 dB.
Anthropometric data
Height and weight were performed and recorded in accordance 
with WHO guidelines.21 Body mass index (BMI) z- scores were 
calculated using the WHO Anthro Plus software V.3.2.2.
Statistical analyses
Data were cleaned, coded and analysed in Stata (V.14.0, Stata 
Corp, Texas, USA). Continuous variables were presented as 
mean with SD or median with IQR. Groups were compared 
using independent t- tests, Mann–Whitney and Kruskal–Wallis 
tests. Post- hoc for pairwise comparisons were performed for 
FEV1 % predicted and age categories, with Tukey’s method 
to adjust for multiple comparisons. Categorical variables were 
reported as proportions and groups were compared using χ2 or 
Fisher’s exact test. Multiple regressions were used to model FEV1 
z- score, adjusting for possible covariates. Significant (p<0.05) 
variables were retained (backward selection) and results from the 
reduced regression model are reported. Normality of residuals 
was accessed using kernel density estimations and visual inspec-
tion of histograms. Results from the models were presented as 
number of observations, regression coefficients (r) with 95% CIs 
and model’s goodness- of- fitness (adjusted R2). Spearman’s rank 
correlation coefficient was used to compare association between 
variables that were not normally distributed or between contin-
uous and non- continuous variables.
resulTs
In all, 333 children with PCD underwent an annual review 
during the study period. Median age at review was 9.8 years, 
52.6% of those reviewed were men and the majority were either 
white British (n=122, 36.6%) or Pakistani and British Pakistani 
(n=121, 36.3%) (table 1, online supplementary figure 1).
Diagnosis of PCD
Median age at diagnosis of PCD was 2.6 years (IQR: 0.5–7.2 
years) (table 1). This was significantly lower in those with dextro-
cardia (n=172) compared with levocardia (n=151) (1.0 year of 
age (IQR: 0.3–3.2, range: 0–14.0) vs 6.0 years (IQR: 2.0–9.0, 
range: 0–16.2), p<0.001). 53.3% of children had dextrocardia 
with almost all having situs inversus totalis, only 12 patients 
(3.7%) had dextrocardia in isolation. CHD was reported in 
13.1% of children spirometry.
Mean (SD) FEV1 z- scores for children with PCD were −1.9 
(1.4) and FVC z- scores were −1.3 (1.5), mean predicted FEV1 
(SD) was 76.8% (table 1). FEV1 z- score was significantly lower in 
older children, with a decrease of 0.6 z- scores for every increase 
of 10 years in age (n=240, regression coefficient=−0.06, 95% CI 
−0.11 to −0.02, p=0.008, adjusted R2=2.9%; figure 1a), 
adjusted for centre of origin, age at diagnosis, sex, cardiac situs 
and presence of cultured pathogens (online supplementary table 
1). Spirometry data from children with CF in 2015 were avail-
able as predicted FEV1 and hence this was used for comparison 
with our patients with PCD.20 Mean predicted FEV1 was signifi-
cantly lower in PCD children compared with CF children up to 
the age of 15 years (p=0.001), with no difference seen in the 
16- to 18- years- old category (p=0.7). The largest difference was 
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Figure 1 a) Age (years) versus FEV1 z- score for 240 children with PCD 
in 2015. (b) Mean (95% CI) % predicted FEV1 of 240 children with PCD 
versus 2970 children with CF in England in 2015, stratified by age group 
(20), (c) BMI z- score versus FEV1 z- score for children with PCD in 2015. 
BMI, body mass index; CF, cystic fibrosis; FEV1, forced expiratory volume 
in one second; PCD, primary ciliary dyskinesia.
Figure 2 Microbiology results taken at annual review by percentage, 
stratified by age category. HI, Haemophilus influenzae; MC, Moraxella 
catarrhalis; PA, Pseudomonas aeruginosa; SA, Staphylococcus aureus; 
SP, Streptococcus pneumoniae.
Figure 3 Proportion of children with PCD with varying degrees 
of hearing loss in different age groups in 2015. PCD, primary ciliary 
dyskinesia.
Table 2 Management of children with PCD in England in 2015
Physiotherapy modality n (%)
n with data 
available
Breathing techniques 10 (3.3) 299
Exercise for airway clearance 2 (0.7) 299
Manual techniques 41 (13.7) 299
PEP physiotherapy (mask/Pari) 96 (32.1) 299
Oscillating PEP 147 (49.2) 299
Other 3 (1.0) 299
Antibiotics
Number of intravenous antibiotic courses in past 
year
95 (29.7) 320
Median (IQR) courses of oral antibiotics 2 (1 to 3) 254
On regular intravenous treatment (every 
3–6 months)
34 (10.6) 320
On antibiotic prophylaxis 189 (58.9) 321
Other treatments
Inhaled corticosteroids 111 (34.2) 325
Bronchodilators 156 (48.3) 323
Nasal rinsing 123 (38.7) 318
PCD, primary ciliary dyskinesia; PEP, Positive expiratory pressure.
in the 5- to 7- year olds, where the mean predicted FEV1 was 
91.3% (SD=15.7%) in CF but was 78.3% (SD=18.6%) in PCD 
(figure 1b).20
Mean (SD) BMI z- scores in children with PCD were normal 
(z- score=0 (1.4)) (table 1). However, children with lower 
BMI also had lower FEV1 z- scores (n=238, regression coef-
ficient=0.35, 95% CI: 0.22 to 0.47, p<0.001, adjusted 
R2=10.8%) (figure 1c).
Microbiology
Microbiology data were available for 312 children, of which 
67% did not culture a respiratory pathogen at annual review. 
Haemophilus influenzae was the most prevalent pathogen 
(17.9%, corresponding to 53.9% of those with a positive 
culture), followed by Staphylococcus aureus (5.1%) and Strep-
tococcus pneumoniae (4.2%), with Pseudomonas aeruginosa 
cultured in 2.6% of children (online supplementary table 2). 
No children cultured non- tuberculous mycobacterium. There 
was no correlation between those culturing respiratory patho-
gens and FEV1 z- scores and no statistically significant differences 
were observed in respiratory pathogens when stratified by age 
category (figure 2).
Audiology
Normal hearing levels were observed in 44.3% of children with 
audiology results available (n=271; 81.4% of all children), 34% 
had mild hearing loss and 21.8% had more significant hearing 
loss. At the time of annual review, 23.6% of children were 
wearing hearing aids. Moderate to profound hearing loss was 
seen in 26.4% of children younger than 6 years of age but in 
only 13.8% of those aged between 16 and 18 years (figure 3). 
Once the children were under the care of the National Chil-
dren’s PCD Management Service, only two of the 333 children 
had ventilation tubes inserted.
Physiotherapy and mucolytic nebulisation
All children were trained to perform, and advised to under-
take, regular age- appropriate airway clearance physiotherapy. 
The majority used either oscillating positive expiratory pres-
sure (PEP) (49.2%) or PEP physiotherapy (32.1%) (table 2). 
Approximately half of children (53.2%) were prescribed nebu-
lised hypertonic saline as a mucolytic agent to aid airway clear-
ance. Children using hypertonic saline had significantly lower 
FEV1 z- scores (mean difference −0.4, 95% CI −0.76 to −0.04, 
p=0.028). Nebulised Dornase Alpha (Pulmozyme, Genentech, 
San Francisco, USA) was used in only 4.9% of children.
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Antibiotics
Thirty per cent of children with PCD had at least one courses of 
intravenous antibiotics over the preceding 12 months. Approxi-
mately 10% of the children were prescribed regular intravenous 
antibiotics (table 2). Those that received intravenous treat-
ment had a lower FEV1 z- score, adjusted for BMI z- score and 
age (n=234, regression coefficient=−0.52, 95% CI: −0.88 to 
−0.16, adjusted R2=17.5%). Children received a median of two 
courses of oral antibiotics over the preceding year (IQR: 1–3). 
59% were prescribed prophylactic antibiotics and of these, over 
half used Azithromycin (59.8%) (table 2, online supplementary 
table 3). A significantly lower mean FEV1 z- score was found in 
children taking prophylactic antibiotics, adjusted for use of anti-
biotics in the last year (intravenous or oral) and cultured patho-
gens (n=162, regression coefficient: −0.66, 95% CI: −1.23 to 
−0.08, p=0.0008, adjusted R2=8.3%).
DIsCussIOn
This study provides detailed characterisation of a large and well- 
defined group of children with PCD, diagnosed and managed 
under the unified, specialised National Children's PCD Manage-
ment Service in England.
Historically, PCD has been considered a mild respiratory 
condition22; however, we report a mean FEV1 of −1.9 z- scores 
in children with the disease in England. Almost a third of chil-
dren required admission for intravenous antibiotics over the 
preceding 12 months with over 10% receiving regular intrave-
nous antibiotics. Further to this, while a recent large interna-
tional PCD cohort found a similar reduction in lung function 
between children with PCD and CF, we showed that % predicted 
FEV1 was significantly lower in those with PCD compared with 
those with CF up to the age of 15 years, as was also observed 
in a smaller Danish cohort study.2 3 23 This suggests that in 
2015, younger children seen by the National Children’s PCD 
Management Service had lower lung function than their Euro-
pean counterparts. However, lung function decline over time 
was steeper in patients with CF and, by the age of 16 to 19 
years, no statistically significant difference was seen between the 
two groups.
Our children had a median age at diagnosis of 2.6 years. This 
is considerably younger than previously reported in the litera-
ture,24 suggesting that the establishment of National Children’s 
PCD Diagnostic Service in 2006 and Management Service in 
2012 might have raised awareness of this rare disease among 
paediatricians. However, newborn screening for CF was intro-
duced in England in 2007 meaning that CF is generally diag-
nosed in infancy, allowing for early initiation of treatment. When 
comparing the spirometry data of our PCD children to those 
with CF, the largest differences in mean FEV1 were in younger 
children (figure 1b). We therefore hypothesise that earlier diag-
nosis and initiation of treatment for PCD may improve the low 
values of FEV1 observed in younger children.
Haemophilus influenzae, as reported in previous studies, 
was the most frequent respiratory pathogen cultured in our 
patients.25 26 Future studies clarifying the impact of chronic 
colonisation with this and other pathogens such as Pseudo-
monas aeruginosa in patients with PCD are needed. While these 
are cross- sectional data, we found no association between any 
cultured pathogen and FEV1. Well- powered longitudinal studies 
will be required to understand the impact of these pathogens on 
patients and, thereby, inform clinicians as to whether they should 
persist in attempting to eradicate them. Contrary to previous 
publications, the prevalence of respiratory pathogen did not vary 
between age groups, in particular there was no increase seen in 
the prevalence of Pseudomonas aeruginosa in older age groups.27
A recently published large international cohort of children 
with PCD28 29 found that patients with lower BMI z- scores have 
lower FEV1 z- scores, which had not been observed previously.30 
Our findings support this novel observation and are similar to 
well- described correlations in children with CF.31 However, the 
majority of patients with CF have pancreatic insufficiency, which 
is not the case in PCD. This would therefore imply that having 
suppurative lung disease, independent of pancreatic issues, may 
impact negatively on nutritional status (or vice versa). These 
findings lead to the hypothesis that intervening on nutritional 
status may have a positive benefit on the respiratory health of 
children with PCD, as is the case in CF,32 and warrants further 
investigation.
Management of children with PCD is challenging due to the 
limited evidence base, with only one published randomised 
control trial (RCT) to date.33 Management is therefore based on 
expert opinion, consensus guidelines and extrapolated from the 
larger evidence base available for patients with CF.15 34 35
All children in the service were advised to undertake regular 
airway clearance physiotherapy.36 Over half the children used 
nebulised mucolytics agents, the vast majority using hyper-
tonic saline. A RCT on use of hypertonic saline in PCD did not 
show improvement on quality of life in patients compared with 
controls33; however, the study did not use a disease- specific 
quality of life questionnaire, was underpowered and the control 
group received normal saline nebulisation, which might in itself 
have been beneficial for the patients.37 We found that children 
on hypertonic saline had a significantly lower FEV1 than those 
not. This is likely due to clinicians reserving its use for children 
with a more severe clinical phenotype; however, further research 
is needed to exclude the possibility that hypertonic saline has a 
negative effect on lung function in children with PCD.
The use of prophylactic antibiotics in PCD remains contro-
versial, as the potential decrease in the number of respiratory 
exacerbations must be balanced against the risk of increasing anti-
microbial resistance. Despite this, in 2015, approximately 60% 
of our children were on prophylactic antibiotics, with over half 
of these using Azithromycin. These children were noted to have 
significantly lower FEV1 than those not on antibiotics. Again, 
clinicians likely reserved the use of prophylactic antibiotics for 
more severe, or frequently exacerbating children. Results from a 
multicentre study assessing the use of prophylactic azithromycin 
in PCD should soon be available and will help inform future 
management.38
Almost a quarter of our children needed hearing aids for 
moderate to profound hearing loss. Hearing seems to improve 
with age but the high proportion of patients with some level of 
hearing loss stresses the importance of regular hearing assess-
ments and ENT follow- up, particularly in early childhood, 
when hearing is fundamental to speech development. Only 2 
out of 333 children in this study had ventilation tubes inserted 
under the care of the Service. The limited evidence for their use 
is both inconclusive and conflicting and a well- designed and 
powered study is needed to investigate this important area of 
management.39–42
The strength of this work is in the large number of well- 
characterised children with PCD evaluated under a nationally 
standardised Management Service. However, the data are cross- 
sectional and therefore do not allow for conclusions to be drawn 
on, for example, the potential benefits of therapeutic interven-
tions or the detrimental impact of culturing particular patho-
gens on clinical outcomes. Detailed longitudinal follow- up of 
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these children are therefore required and will help inform both 
management guidelines and therapies to be evaluated in future 
RCTs. Comparisons of lung function data between children with 
PCD and CF were limited to the data provided by the UK CF 
Registry (ie, GLI- based spirometry measurements) and we were 
therefore unable to adjust CF data for potential confounders.
COnClusIOns
Our data suggest that, far from being a mild respiratory condi-
tion, children with PCD have worse lung function than those 
with CF, particularly at an earlier age. Those with a lower BMI 
have a significantly lower FEV1; therefore, nutritional status 
should be considered in their management. Well- designed and 
powered RCTs on the management of PCD are needed to inform 
best clinical practice.
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